Table 1.
GI50 of the synthesized compounds over MCF7 and HCT116 cancer cell lines.
| Compd. | GI50 (μM) * | |
|---|---|---|
| MCF7 | HCT116 | |
| 4a | >10 | >10 |
| 4b | >10 | >10 |
| 4c | >10 | >10 |
| 4d | >10 | >10 |
| 4e | >10 | >10 |
| 4f | >10 | >10 |
| 4g | >10 | >10 |
| 4h | >10 | >10 |
| 4i | 3.35 ± 0.101 | >10 |
| 4j | >10 | >10 |
| 4k | 3.03 ± 0.061 | >10 |
| 4l | 9.00 ± 0.347 | >10 |
| 4m | >10 | >10 |
| 4n | >10 | >10 |
| 8a | 0.06 ± 0.014 | 1.19 ± 0.035 |
| 8b | >10 | >10 |
| 8c | 3.73 ± 0.075 | 1.22 ± 0.141 |
| 8d | 1.89 ± 0.26 | >10 |
| 8e | 4.37 ± 0.359 | >10 |
| 8f | 0.89 ± 0.209 | 0.92 ± 0.114 |
| 8g | 1.17 ± 0.059 | 1.25 ± 0.037 |
| 8h | 0.23 ± 0.015 | 0.33 ± 0.042 |
| 8i | 0.16 ± 0.013 | 1.08 ± 0.006 |
| 8j | 0.75 ± 0.142 | >10 |
| 8k | 1.13 ± 0.003 | 1.38 ± 0.086 |
| Sorafenib | 11.2 [31] | - |
| Irinotecan | 0.35 ± 0.069 | 0.62 ± 0.003 |
* All values are expressed as mean ± standard error (n = 3).